Bioline Rx Ltd ADR

BLRXNASDAQ · USD
1.30USD0.00 (-3.71%)
122

Bioline Rx Ltd ADR (BLRX) Historical Volatility

BLRX's 30 day historical volatility is 53.82%, in the 47th percentile of readings over the past year. This is an average percentile, meaning Bioline Rx Ltd ADR shares have moved roughly in line with their typical range. BLRX's 30 day implied volatility sits at 0.01%, with an IV Rank of 2.38%, leaving IV 53.81 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking BLRX historical volatility helps you see how much Bioline Rx Ltd ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, BLRX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor BLRX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. BLRX's 30 day historical volatility, or BLRX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing BLRX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Historical Volatility

HV Percentile
47thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)53.82%

HV Percentile47th

Implied Volatility (30d)0.01%

IV Rank2.38%

IV Minus HV-53.81%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →